Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma Clinical Trial

Official title:

Monitoring of Treatment Related Toxicities From Oral Targeted Agents and Immunotherapy Among Patients With Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03229083
• Other study ID #: UGUK 17036
• Status: Recruiting
• Phase: N/A
• Start date: July 24, 2019
• Est. completion date: February 1, 2025

Study information

• Verified date: November 2023
• Source: University of Rochester
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metastatic renal cell carcinoma (RCC). Additionally for collection of preliminary data on treatment-related toxicities, quality of life, distress level, and drug adherence.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: February 1, 2025
• Est. primary completion date: November 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of histologically confirmed renal cell carcinoma of any subtype with either pathological or radiographic evidence of metastatic disease
• Greater than 18 years of age
• A participating Wilmot Cancer Center oncologist has determined that candidate should be started on either oral targeted therapy or immunotherapy for treatment of their advanced RCC; this can be for first-line or any subsequent line therapy
• Able to provide written informed consent
• Proficient in the English language and self-reports as literate
• Must have an active email address or access to a smart device on which text messages can be received

Exclusion Criteria:

• Women cannot be breast-feeding
• Does not have regular access to the internet
• Unable to come to the Wilmot Cancer Center for appointments every 3-4 months for routine visits with their primary oncologist
• Subjects who were on the study previously will not be allowed to re-enroll in the event of a treatment change

Related Conditions & MeSH terms

• Advanced Renal Cell Carcinoma
• Carcinoma
• Carcinoma, Renal Cell

Intervention

Other:
• Carevive software
In this study, Carevive will deliver a link to subjects so that an online survey can be completed. The survey will occur weekly for the first 12 weeks of the study and will be spaced out to every other week thereafter. The questions will mostly focus on side effects from their cancer therapy, as well as a few questions about drug compliance and healthcare utilization. After completion of the survey, the subject will be given a care plan with at home self-management options for drug-related toxicities.

Locations

Country	Name	City	State
United States	University of Rochester - Wilmot Cancer Institute	Rochester	New York

Sponsors (1)

Lead Sponsor	Collaborator
University of Rochester

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Carevive Survey Usage Rates	Carevive software will track subject compliance with survey logins and whether they access the generated care plans. The percentage of times logged in out of the number of study recommended logins will be tabulated. Also, the percentage of times a careplan was accessed out of the number of times it was offered will be determined.; To determine the practicality of the intervention, by analyzing the reasons why subjects fail to self-report treatment-related toxicities or utilize software generated care plans after enrollment.; To assess the acceptability of this intervention with validated patient reported usability scores of the software.; To determine potential implementation obstacles of the intervention, by assessing the reasons eligible study candidates decline participation.	48 weeks
Primary	Reasons Participants Do Not Complete Survey or Utilize Care Plans	After missing a survey, subjects will be asked the reason at their following login. The reason provided will be sorted into pre-specified categories and presented as a percentage.	48 weeks
Primary	Average Usability Score Using the Software Usability Scoring System	At the 48 week time point or at the point of subject withdrawal from study, they will be asked to take the System Usability Scale. The survey provides us with a score of between 0 and 40 which is then multiplied by 2.5 to convert to a scale of 0 to 100. A SUS score above a 68 would be considered above average and anything below 68 is below average.	48 weeks
Primary	Reasons for Declining Study Participation	If a subject declines to participation in the study, he/she will be asked to provide a reason for declination. If willing, we will have them sign a separate consent with a space to write in their reason. The reason provided will be sorted into pre-specified categories and presented as a percentage.	48 weeks
Secondary	Patient Reported Toxicities Using PRO-CTCAE Questions	Patient reported toxicity data will be collected via Carevive surveys weekly for the first 12 weeks and then every other week for another 36 weeks. We will not deliver the PRO-CTCAE in its entirety but will specifically ask about the following common toxicities that are experienced with oral targeted therapy and immunotherapy: diarrhea, nausea, vomiting, fatigue, hand/foot syndrome, rash, abdominal pain, anorexia, mouth sores, cough and shortness of breath.	48 weeks
Secondary	Clinician Reported Toxicities Using CTCAE	Toxicities will also be formally assessed in-office every 3-4 months using CTCAE scoring. The categories chosen are common toxicities that occur with oral targeted therapy and immunotherapy: diarrhea, nausea, vomiting, fatigue, hand/foot syndrome, rash, abdominal pain, appetite, mouth sores, cough and shortness of breath	48 weeks
Secondary	Quality of Life Determination Using the FKSI-DRS Survey	Subjects will be asked to fill out the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-DRS) at baseline and approximately every 3 months in-office.	48 weeks
Secondary	Distress Level Using the NCCN Distress Thermometer	The subject will be asked to rate their distress level in-office using the NCCN Distress Thermometer, which is a 1 to 10 numerical scale. This will be delivered during routine office visits approximately every 3 months on a tablet.	48 weeks
Secondary	• Health Care Utilization Assessment By Quantification of Health Care Visits or Hospitalizations	Health care utilization will be self-reported by the subject through CareVive software monthly, in addition at the end of the study or at time of withdrawal, a search of the electronic medical record will be performed to determine the number of calls made to oncology care providers and the number of visits to the oncologist during the study period.	48 weeks